Fairfax Diagnostics wants you to have all the knowledge you need to make informed decisions following PGT results. We have genetic counselors on staff ready to provide post-test counseling.
Every parent hopes to have a healthy child whether through natural conception or IVF. The good news is most babies are born healthy. But for some couples who have experienced recurrent obstacles on the road to conception, preimplantation genetic testing (PGT) at Fairfax Diagnostics is here for you. As pioneers in the fields of reproductive genetics and molecular diagnostics, Fairfax Diagnostics combines decades of biomedical experience and advanced technology to provide results that matter to patients undergoing IVF treatment.
PGT at Fairfax Diagnostics uses high resolution Next Generation Sequencing technology (NGS).
Results available in as little as 7 business days after receiving sample.
Our lab is headquartered conveniently in Fairfax, Virginia within the Northern Virginia and Washington, DC metropolitan area.
Fairfax Diagnostics has over 38 years of experience in the field of assisted reproductive technology. Our expert team of molecular and clinical geneticists have been at the forefront of pioneering PGT test design, validation, and clinical application.
Fairfax Diagnostics was founded in 1984 in partnership with Genetics & IVF Institute as a complete embryo testing solution for couples pursuing IVF.
We maintain a zero-misdiagnosis rate in all three PGT programs at Fairfax Diagnostics. All results are reviewed by a team molecular and clinical PhD and MD experts.
To get started with PGT at Fairfax Diagnostics contact us today.
Looking for more information on PGT at Fairfax Diagnostics? Here are some frequently asked questions.
Embryos created using standard IVF protocols with intracytoplasmic sperm injection (ICSI) are grown in the laboratory for 5 to 6 days until they form an early embryo called a blastocyst. The embryo is subsequently biopsied to remove a few cells from the outer layer, also called a trophectoderm, which is destined to form the placenta.
After biopsy, embryos are frozen and stored while the cell’s genetic material is tested for abnormalities using PGT. After PGT analysis, results are evaluated by the medical and genetics teams, then a Fairfax Diagnostics genetic counselor will discuss results with the patient/couple and a frozen embryo transfer (FET) cycle is planned for the healthy embryo(s).
For couples pursuing testing for aneuploidy (PGT-A) and structural chromosome rearrangements (PGT-SR), a method called Next Generation Sequencing (NGS) is used. This technology determines the amount of DNA present for each chromosome in cells removed from the developing embryo. Gains or losses of complete chromosomes or parts of chromosomes are identified by NGS and a dedicated software algorithm. For gender determination, NGS testing can determine the presence the sex chromosomes, XX or XY, for females or males respectively.
Yes. Substantial data indicates that PGT does not increase birth defects over that of the general population. Removal of a few cells from the outer layer (trophectoderm) does not alter the ability of that embryo to develop a normal pregnancy; in fact, biopsy avoids disrupting the embryo’s inner most cells that will form the fetus. In embryos undergoing PGT testing, many fewer pregnancies will end in miscarriages due to chromosomal disorders since abnormalities are identified prior to embryo transfer.
Fairfax Diagnostics requires counseling for all PGT-M and SR patients. We also recommend consultation for PGT-A, if necessary.